Achilles Therapeutics Plc ADR [NASDAQ: ACHL] surged by $0.03 during the normal trading session on while it closed the day at $1.42.
Achilles Therapeutics Plc ADR stock has also gained 2.16% of its value over the past 7 days. However, ACHL stock has inclined by 35.24% in the 3 months of the year. Over the past six months meanwhile, it has gained 98.60% and gained 24.56% year-on date.
The market cap for ACHL stock reached $58.36 million, with 41.10 million shares outstanding and 37.95 million shares in the current float. Compared to the average trading volume of 1.18M shares, ACHL reached a trading volume of 4311502 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Achilles Therapeutics Plc ADR [ACHL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ACHL shares is $0.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ACHL stock is a recommendation set at 4.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Achilles Therapeutics Plc ADR shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on April 05, 2024. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Overweight. The new note on the price target was released on April 26, 2021, representing the official price target for Achilles Therapeutics Plc ADR stock. Previously, the target price had yet another raise to $23, while Oppenheimer analysts kept a Outperform rating on ACHL stock.
The Average True Range (ATR) for Achilles Therapeutics Plc ADR is set at 0.03 The Price to Book ratio for the last quarter was 0.57, with the Price to Cash per share for the same quarter was set at 2.09.
ACHL stock trade performance evaluation
Achilles Therapeutics Plc ADR [ACHL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.16. With this latest performance, ACHL shares gained by 2.90% in over the last four-week period, additionally plugging by 98.60% over the last 6 months – not to mention a rise of 15.45% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ACHL stock in for the last two-week period is set at 73.47, with the RSI for the last a single of trading hit 76.39, and the three-weeks RSI is set at 71.76 for Achilles Therapeutics Plc ADR [ACHL]. The present Moving Average for the last 50 days of trading for this stock 1.2779, while it was recorded at 1.3950 for the last single week of trading, and 1.0004 for the last 200 days.
Achilles Therapeutics Plc ADR [ACHL]: An insightful look at the core fundamentals
Achilles Therapeutics Plc ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.04 and a Current Ratio set at 6.04.
Achilles Therapeutics Plc ADR [ACHL]: Institutional Ownership
There are presently around $86.10%, or 92.10%% of ACHL stock, in the hands of institutional investors. The top three institutional holders of ACHL stocks are: SYNCONA PORTFOLIO LTD with ownership of 11.09 million shares, which is approximately 27.4728%. FCPM III SERVICES B.V., holding 2.39 million shares of the stock with an approximate value of $$1.95 million in ACHL stocks shares; and FCPM III SERVICES B.V., currently with $$1.31 million in ACHL stock with ownership which is approximately 3.9848%.
